Comparing LYVE-1 and D2-40 expression in small cell lung carcinomas (SCLC); association with clinical parameters and lymphatic invasion Source: Annual Congress 2011 - Lung development and neoplasia Year: 2011
Espression of vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt1, VEGF-R2-Flk1) in non small cell (NSCLC) and small cell lung carcinomas (SCLC). Correlation with clinical outcome Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008
An analysis of mRNA and long non-coding RNA (lncRNA) expression during the progression from pre-invasive lesions (PL) to invasive squamous cell carcinoma (SqCC) of the bronchus Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making Year: 2013
Biological role of prognostic microRNAs (miRNAs) in squamous lung carcinoma (SCC) cells Source: International Congress 2015 – Latest news on miRNAs in pulmonary research Year: 2015
Analysis of overall survival (OS) in two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut) Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014
Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung: LUX-Lung 8 (LL8), a phase III trial Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015
Prognostic value of three-microRNA expression profile in early stage squamous cell lung cancer (SqCLC) Source: Annual Congress 2010 - New mechanisms and markers in human lung cancer Year: 2010
Comparing the prognostic impacts of angiogenesis, lymphangiogenesis and lymphatic invasion (LI) in small cell lung carcinomas (SCLC) Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008
Predicting activity of EGFR (epidermal growth factor receptor) inhibitors in diffuse bronchiolo-alveolar carcinoma or so-called pneumonic adenocarcinoma Source: Annual Congress 2006 - Bronchiolo-alveolar carcinoma Year: 2006
Prevalence of silent brain metastasis (BM) in the initial staging of non-small cell lung carcinoma (NSCLC) Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients Year: 2011
Carbonic anhydrase 9 expression (CA9e) profile combined with growth patterns (GPs) in non-small cell lung cancer (NSCLC) identifies a group of patients with an extremely poor prognosis Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology Year: 2005
Molecular epidemiology in non small cell lung cancer (NSCLC) tumors: implication of gender and histological features Source: Eur Respir J 2006; 28: Suppl. 50, 335s Year: 2006
European treatment guidelines: small cell lung cancer (SCLC) Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009
Response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) according to their serum levels of chosen tumor markers (CYFRA 21-1 (CY21), CEA and NSE) Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001
Expression of vascular endothelial growth factor (VEGF) and association with lymphangiogenesis in non small cell (NSCLC) and small cell lung carcinomas (SCLC) Source: Eur Respir J 2006; 28: Suppl. 50, 386s Year: 2006
Is it possible to predict response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) on the basis of serum CYFRA 21-1 level (sCY21)? Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002
C-erbB-3 expression in non small cell lung cancer (NSCLC) patients treated by erlotinib Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
Validation of the prognostic value of growth pattern classification in operated non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Actual challenges in thoracic surgery Year: 2010
FEV1 is not a prognostic marker in operated patients with stage I or II non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Surgery for lung cancer: pre-operative evaluation and results Year: 2011
C-kit (CD 117): a new prognostic factor in small cell lung cancer (SCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 478s Year: 2001